Tag Archive | "oropharyngeal cancer"

Aspen Dental Practices Donate More Than $20,000 To The Oral Cancer Foundation For Oral Cancer Awareness Month

Thursday, June 16, 2016

0 Comments

Source: www.pharmiweb.com.org Author: Aspen Dental   SYRACUSE, N.Y., May 31, 2016 /PRNewswire/ — Aspen Dental–branded practices will donate $22,375 to The Oral Cancer Foundation (OCF) as part of a program that contributed $5 for each ViziLite® oral cancer screening conducted during April for Oral Cancer Awareness Month. In total, more than 4,000 patients were screened across more […]

Continue reading...

Nivolumab Improved Survival For Patients With Head and Neck Squamous Cell Carcinoma

Tuesday, April 19, 2016

0 Comments

Source: www.aacr.org Author: AACR Newsroom Staff   NEW ORLEANS — Treatment with the immunotherapeutic nivolumab (Opdivo) improved survival for patients with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy compared with single-agent chemotherapy of the investigator’s choice, according to results from the CheckMate-141 phase III clinical trial presented here […]

Continue reading...

The Oral Cancer Foundation’s Founder, Brian R. Hill, honored by the Global Oral Cancer Forum – International oral cancer community honor his accomplishments in the field.

Friday, March 11, 2016

0 Comments

Source: www.prnewswire.com Author: The Oral Cancer Foundation   NEWPORT BEACH, Calif., March 10, 2016 /PRNewswire-USNewswire/ — At the recent Global Oral Cancer Forum (GOCF), Brian R. Hill, Executive Director and Founder of the Oral Cancer Foundation (OCF), was honored for his work as an advocate and innovative thinker in the oral cancer arena. The GOCF organizers […]

Continue reading...

Immunotherapy Continues to Advance in Head and Neck Cancer

Monday, February 29, 2016

0 Comments

Source: www.onclive.com Author: Megan Garlapow, PhD   Concomitant administration of motolimod with cetuximab (Erbitux) increases the innate and adaptive immune response in the blood and the tumor microenvironment in head and neck squamous cell carcinoma (HNSCC), overcoming negative prognostic biomarkers of cetuximab therapy alone, according to the biomarker data from a recent phase Ib clinical […]

Continue reading...

NCCN Is ‘Vague,’ So Study Clarifies H&N Cancer Follow-up

Tuesday, February 23, 2016

0 Comments

Source: www.medscape.com Author: Nick Mulcahy   Clinical guidelines can sometimes be slow to respond to epidemiology. Take the case of oropharyngeal cancers that are associated with human papillomavirus (HPV) infection. They are increasingly common in the United States and, as several studies have demonstrated, have better survival than cancers of this type that are not […]

Continue reading...

Excitement at new cancer treatment

Monday, February 22, 2016

0 Comments

Source: www.news.doximity.com Author: James Gallagher A therapy that retrains the body’s immune system to fight cancer has provoked excitement after more than 90% of terminally ill patients reportedly went into remission.   White blood cells were taken from patients with leukaemia, modified in the lab and then put back. But the data has not been […]

Continue reading...

HPV vaccination rates are low, especially in Kansas and Missouri, and cancer experts are alarmed

Thursday, February 18, 2016

0 Comments

Source: www.kansascity.com Author: Lisa Gutierrez The HPV vaccine is recommended for girls and boys starting at ages 11 to 12. But in state-by-state comparisons, children in Kansas and Missouri rank at or near the bottom of the list. John Amis The Associated Press   The University of Kansas Cancer Center recently joined nearly 70 other […]

Continue reading...

HPV16 Antibodies Signal Even Better Oral Cancer Outcomes

Wednesday, June 17, 2015

0 Comments

Source: www.medscape.com Author: Neil Osterweil   Another prognostic tool may be in the offing for clinicians to use in evaluating patients with oropharyngeal cancers, new research suggests. The presence in serum of three antibodies to human papillomavirus type 16 (HPV16) was predictive of better progression-free and overall survival in these patients, according to Kristina R. […]

Continue reading...

NIH-funded study finds new potential drug targets by uncovering a range of molecular alterations in head and neck cancers

Tuesday, March 10, 2015

0 Comments

Source: www.nih.gov Author: Staff   Investigators with The Cancer Genome Atlas (TCGA) Research Network have discovered genomic differences — with potentially important clinical implications — in head and neck cancers caused by infection with the human papillomavirus (HPV). HPV is the most common sexually transmitted virus in the United States, and the number of HPV-related […]

Continue reading...

HPV Related Cancers Increase in Men

Wednesday, February 18, 2015

0 Comments

Source: scientificamerican.com Author: Robin Lloyd A vaccine to protect against the most dangerous strains of human papillomavirus (HPV), which cause almost all cervical cancers, as well as many cases of other cancers and genital warts in both sexes, won the approval of the U.S. Food and Drug Administration nearly nine years ago. The Centers for Disease […]

Continue reading...